Replimune (RMNI) Stock Surges 40% on FDA Approval Path Agreement

AI Summary

Replimune (RMNI) experienced a 40% increase in stock value following the announcement of an agreement with the FDA regarding its approval path. This significant rise in market interest may influence investor sentiment toward biotech stocks. The agreement is crucial as it could potentially expedite the drug development process and reduce uncertainties regarding regulatory outcomes. Such developments often lead to increased trading volumes and market engagement in the sector.